Roche Plans Clinical Trial With MorphoSys-Generated Alzheimer Antibody

MorphoSys AG (Frankfurt Stock Exchange: MOR; Prime Standard Segment; TecDAX) announced today that its partner Roche has filed all necessary applications to commence a European Phase 1 clinical trial with a HuCAL®-derived antibody to treat Alzheimer's disease. The HuCAL® antibody targets abnormal build-ups of amyloid beta protein in cerebral tissue, which are typical of Alzheimer's patients, and is intended to help remove them. The applications filing to commence clinical trials triggers a clinical milestone payment from Roche to MorphoSys. Further financial details were not disclosed.